comparemela.com

Latest Breaking News On - Cartesian therapeutics - Page 1 : comparemela.com

Cell therapy reckoning: An unmet need remains in oncology

Cell therapy reckoning: An unmet need remains in oncology
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Germany
United-states
German
American
James-waldron
Max-bayer
Helen-floersh
Zachary-roberts
Cindy-perettie
William-blair
Sami-corwin
Roche-genentech

Adhoc: Reinet Investments SCA: CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 AND PROPOSED DIVIDEND

Reinet Investments SCA / Key word(s): Quarter Results Consolidated audited financial results for the year ended 31 March 2024 and proposed dividend 28-May-2024 / 07:35 CET/CEST Release

China
Netherlands
Russia
Berlin
Germany
Belarus
South-africa
Japan
Ukraine
Canada
Florida
United-states

CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 AND PROPOSED DIVIDEND

Reinet Investments SCA / Key word: Quarter Results CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 AND PROPOSED DIVIDEND 28-May-2024 / 07:35 CET/CEST Release of.

China
United-states
Netherlands
Johannesburg
Gauteng
South-africa
South-carolina
Liang-du
Shanxi
Denmark
Clearstream
North-west

CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 AND PROPOSED DIVIDEND - adhoc - Börsennachrichten

Reinet Investments SCA Key word Quarter Results CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 AND PROPOSED DIVIDEND 28May2024 0735 CETCEST Release of an ad hoc announcement

China
South-africa
Clearstream
North-west
Beijing
Canada
North-carolina
United-states
Singapore
Ukraine
Amsterdam
Noord-holland

HC Wainwright Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $54.00 target price on the stock. A number of other research firms have also issued reports on RNAC. Needham & Company LLC reaffirmed a buy rating and […]

United-states
American
Leerink-partnrs
Hall-laurie
Timothya-springer
Securities-exchange-commission
American-international-group-inc
Delphi-financial-group-inc
Needham-company
Cartesian-therapeutics-inc
Sg-americas-securities
Cartesian-therapeutics

vimarsana © 2020. All Rights Reserved.